Safety and efficacy of rituximab in adult immune thrombocytopenia: Results from a prospective registry including 248 patients

Blood

Volumn 124, Issue 22, 2014, Pages 3228-3236

  Khellaf, Mehdi ^a   Charles Nelson, Anaïs ^b   Fain, Olivier ^c   Terriou, Louis ^d   Viallard, Jean Franҫois ^e   Cheze, Stéphane ^f   Graveleau, Julie ^g   Slama, Borhane ^h   Audia, Sylvain ⁱ   Ebbo, Mikael ^j   Le Guenno, Guillaume ^k   Cliquennois, Manuel ^l   Salles, Gilles ^m   Bonmati, Caroline ⁿ   Teillet, France ^o   Galicier, Lionel ^p   Hot, Arnaud ^q   Lambotte, Olivier ^r   Lefrère, Franҫois ^s   Sacko, Salimatou ^b   Kengue, Dieudonné Kilendo ^b   Bierling, Philippe ^a,b   Roudot Thoraval, Franҫoise ^b   Michel, Marc ^a   Godeau, Bertrand ^a   more..

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d UNIV LILLE   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f CHU CÔTE DE NACRE   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER D AVIGNON   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

^k UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^l UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^m UNIVERSITÉ LYON 1   (France)

ⁿ UNIVERSITY HOSPITAL OF NANCY   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p SAINT LOUIS HOSPITAL   (France)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r BICÊTRE HOSPITAL   (France)

^s HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPHENHYDRAMINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CAUSE OF DEATH; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; OFF LABEL DRUG USE; PARESTHESIA; PHYSICIAN; PREDICTION; RASH; REGISTER; SUSTAINED DRUG RELEASE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; REGISTRIES; TREATMENT OUTCOME;

EID: 84911408335     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-582346     Document Type: Article

References (33)

1. Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013;2013:276-82.
2. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
3. McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163(1):10-23.
4. Godeau B, Stasi R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia? Presse Med. 2014;43(4 Pt 2):e79-e85.
5. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
6. George JN. Sequence of treatments for adults with primary immune thrombocytopenia. Am J Hematol. 2012;87(Suppl 1):S12-S15.
7. Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol. 2011;86(3):278-291.
8. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
9. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
10. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-969.
11. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma. 2009;50(7):1083-1095.
12. Aksoy S, Dizdar O, Hayran M, Harputluoʇlu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50(3):357-365.
13. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-4840.
14. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
15. Gottenberg JE, Ravaud P, Bardin T, et al; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632.
16. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
17. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92(12):1695-1698.
18. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329-334.
19. Mahévas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013;88(10):858-861.
20. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
21. Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins. Haute autorité de santé. Octobre 2009. http://www.has-sante.fr. Accessed October 8, 2014.
22. Venna N, Gonzalez RG, Camelo-Piragua SI. Case records of the Massachusetts General Hospital. Case 11-2010. A 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging. N Engl J Med. 2010;362(15):1431-1437.
23. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358(9292):1511-1513.
24. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149(1):3-13.
25. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol. 2009;146(1):120-122.
26. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
27. Vo KH, Waddell JA, Suda KJ. Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother. 2011;45(5):e29.
28. Millward PM, Bandarenko N, Chang PP, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005;45(9):1481-1486.
29. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol. 2010;47(2):180-186.
30. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol. 2009;84(7):414-417.
31. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386-398.
32. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930.
33. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: Three different regimens. Am J Hematol. 2009;84(10):661-665.